Abstract: A compound of Formula (I): wherein R is a linkage independently selected from (CH2)12 or (CH2)4O3; and acid addition salts, solvates and hydrates thereof. The compounds have unusually high affinity for muscarinic receptors, and exhibit agonist activity useful in the treatment of neurological and other disorders, in which stimulating cholinergic activity is desirable.

Abstract: Apparatus for generating vortices to control the flow of air across a airfoil of an aircraft includes a series of pressure active regions arranged along the leading edge of the airfoil. The pressure active regions include spaced apart valves connected to a source of vacuum, a controller for activating the valves, and sensors for sensing air pressure. The controller is configured to activate the valves in response to the pressure sensed by the sensors, wherein the spaced apart valves are connected to a source of pressurized air as well as to the source of vacuum.

Abstract: A venting-membrane system for mitigating blast pressure generated from a blast force on a wall structure. The venting-membrane system having a framework including a plurality of parallel structural members defining a wall structure having an interior surface and an exterior surface. At least one inflatable enclosure attached to the interior surface of the wall; and at least one inflatable enclosure attached to the exterior surface of the wall wherein the at least one inflatable enclosure attached to the interior surface of the wall is in communication with the at least one inflatable enclosure attached to the exterior surface of the wall.

Abstract: A compound of formula (I): wherein, R1 is independently selected from methyl and ethyl and R2 is independently selected from hydrogen, alkyl, and substituted alkyl. The compound is capable of functioning as a ligand and complexing with paramagnetic Fe(III) ion for use as a second-sphere contrast enhancing agent for magnetic resonance imaging of tissue. The present invention also relates to a method of administering the second sphere contrast agent.

Abstract: A method for producing 2-substituted glycerols having various levels of hydroxy group protection by opening dihydroxyacetone dimer in a nonaqueous, non-protic environment with a composition that initially protects both of the liberated 1,3-dihydroxy groups to form di-ether containing ketone monomers which can then be conveniently subjected to ketone addition reactions and standard chemical functional group manipulations.

Abstract: A compound of formula (I): ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are selected independently from hydrogen, alkyl, and alkyl substituted with one or more --O-- atoms, or where R.sup.1, R.sup.2 and R.sup.3, R.sup.4 are ring residues. The compound is capable of functioning as a ligand and complexing with paramagnetic Fe(III) ion for use as a second-sphere contrast enhancing agent for magnetic resonance imaging of tissue, and a method of administering the second sphere contrast agent.

Abstract: A compound of Formula (I): ##STR1## wherein R is a linkage independently selected from (CH.sub.2).sub.12 or (CH.sub.2).sub.4 O.sub.3 ; and acid addition salts, solvates and hydrates thereof. The compounds have unusually high affinity for muscarinic receptors, and exhibit agonist activity useful in the treatment of neurological and other disorders, in which stimulating cholinergic activity is desirable.

Abstract: A system and method is provided for optimizing a laser light fractionation during photodynamic therapy of a tumor. The tumor is destroyed through the production of singlet oxygen and successful photodynamic therapy treatment requires the maintenance of tumor oxygen above a specified critical level. Depending on the tumor, the photosensitizer concentration, and the laser fluence, sustained irradiation of the tumor will deplete the oxygen below the critical level. When the laser is turned off, oxygen diffuses into the tumor to provide sustained levels of singlet oxygen. The control system controls the operation cycle of the laser and the various surgical parameters. Data regarding the sensitizer, the laser characteristics, and the oxygen features of the tumor are input into the control system for simulation of the PDT treatment. As part of the simulation, the optimal fractionation cycle for the laser is predicted. The data may be adjusted for conducting additional simulations.

Abstract: An open flow helium cryostat system for cooling a sample crystal to be examined using X-ray diffraction, neutron diffraction, or a similar method. The cryostat system including a primary helium supply to provide a first stream of liquid helium onto the sample crystal and a secondary helium supply to provide a second stream of gaseous helium around at least a portion of the primary helium supply at a temperature warmer than the first stream of liquid helium to prevent the formation of ice on the sample crystal.

Abstract: An electronic battery equalization circuit that equalizes the voltages of a plurality of series connected batteries in a battery pack. The current waveform is in the shape of a ramp for providing zero current switching. The transformer has a primary winding circuit and at least one secondary winding circuit. In one embodiment, each secondary winding circuit is connected to a different pair of batteries. The equalizing current is provided to the lowest voltage batteries in one half of the battery pack during one half of the charging cycle. The equalizing current is then provided to the lowest voltage batteries in the other half of the battery pack during the other half of the charging cycle. In another embodiment, each secondary winding circuit is connected to a different single battery. The equalizing current is supplied to a lowest voltage battery in the battery pack during each half of the switching cycle.

Abstract: A method of electroless plating at least one homogeneous metal coating in a predetermined pattern on a solid substrate surface having pendant hydroxy groups. The method includes the steps of providing a first monatomic metal layer in a predetermined pattern on the solid substrate surface having pendent hydroxy groups and then immersing the solid substrate surface in a bath containing a chemical reducing agent to build up the at least one homogeneous metal coating only on the monatomic metal layer.

Abstract: An implantable bioartificial pancreas device having an islet chamber containing glucose responsive and insulin-secreting islets of Langerhans or similar hormone secreting cells, one or more vascularizing chambers open to surrounding tissue, a semi-permeable membrane between the islet and vascularizing chambers that allows passage of small molecules including insulin, oxygen and glucose and does not allow passage of agents of the immune system such as white cells and antibodies, the vascularizing chambers containing a growth factor soaked fibrous or foam matrix having a porosity of about 40 to 95%, the matrix providing small capillary growth and preventing the blood from clotting in the lower chamber.

Abstract: A long range surface plasmon resonance sensor for use in biological, biochemical or chemical testing. The sensor includes a first dielectric medium and a second dielectric medium having an index of refraction approximately matching the first dielectric medium. A double-grating structure is located between the first dielectric medium and the second dielectric medium. A beam of electromagnetic radiation is introduced into the second dielectric medium in a manner which causes long range surface plasmon resonance to occur such that the beam of radiation suffers attenuated total reflection. The characteristics of the resonance dependent upon the reaction between the bonding layer and the targeted bonding molecule are then detected.

Abstract: A battery charger control system and method for maximizing output power to a battery. This is achieved by ensuring operation at either the maximum allowable input current or the thermal limit imposed by the battery charger using an on-line controller. In the invention, the thermal limit is determined by the junction temperatures of the two main IGBT's. Because direct measurement of these temperatures is impractical, they must be calculated by a computer algorithm that uses various on-line measurements. Test results for a 8 kW battery charger indicate reduction in the bulk charging time from conventional battery chargers of about 26% when charging a set of NiFe batteries.

Abstract: An improved four-bar knee joint mechanism for use in knee disarticulation prosthesis is shown, including a coupler link forming a negative angle with the horizontal when said knee joint mechanism is in its stance position, an anterior link, a fixed link in a horizontal position when said knee joint is in the extended or stance position, and a posterior link, the dimensions of the links and the angle the coupler link makes with the horizontal being chosen to optimize the instant center of the mechanism.

Abstract: A compound having nonlinear optical properties of the general formula:Ar.sup.1 CR.sup.1 .dbd.CR.sup.2 (Ar.sup.2 CR.sup.3 .dbd.CR.sup.4).sub.n Ar.sup.3 (I)wherein, n represents a whole number; R.sup.1, R.sup.1, R.sup.3 and R.sup.4 groups are independently selected from H, branched aliphatic, straight chain aliphatic, branched silane or straight chain silane; Ar.sup.1 and Ar.sup.3 are aromatic radicals having a substituent in at least one position adjacent to a site of attachment of the C.dbd.C double bond and having at least one electron withdrawing or electron donating substituent in at least one of the remaining positions; Ar.sup.2 is an aromatic radical having a substituent in at least one position adjacent to a site of attachment of the C.dbd.C double bond; with the proviso that the substituent in at least one position adjacent to the site of attachment of the C.dbd.C double bond and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 groups are sufficiently large to cause Ar.sup.1, Ar.sup.2 and Ar.sup.

Abstract: A muscarinic agonist compound having the formula (I) or (II) below or a pharmaceutically acceptable salt thereof: ##STR1## where R is (trans) 3-methyl-2-penten-4-ynyl, (cis)3-methyl-2-penten-4-ynyl, 2-butynyl, 2-methylbutenyl, 3-methylpropynyl, phenylpropynyl, butynyl; or ##STR2## where R' is butynyl.

Abstract: Families of Diels Alder adducts and of metal complexes of Diels Alder adducts, which are useful as particularly active compounds for use in photodynamic therapy, are disclosed. The Diels Alder adducts and a preferred family of metal complexes have the structures of Formulas 1, 2, 3 and 4, below: ##STR1## where R1, R2, R3 and R4 can be the same or different, and each is methyl, ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, R5, R6 and R7 can be the same or different, and each is ethyl or an amino acid moiety which is a part of an amide produced by reaction between an amine function of a naturally occurring amino acid and a carbonyl function of the adduct, M comprises metal cation.

Abstract: A method of delivering a medicament to the surface of a cancer cell and transferring the medicament into the cancer cell using an activated plasminogen activator material such as a plasminogen activator inhibitor type-1 or type-2 (PAI-1, PAI-2). The medicament is coupled to PAI-1 or PAI-2 to form a reaction product that is coupled with the urokinase plasminogen activator (uPA) that is bound to the cell surface by the uPA receptor (uPAR). The medicament is coupled to PAI-1 or PAI-2 (for example, using a preserving agent such as saporin) in such a way that the medicament does not interfere with active sites responsible for binding to uPA or LRP proteins responsible for the internalization of the plasminogen activator material/conjugated medicament. The conjugated medicament prevents the conversion of the plasminogen activator inhibitor material into its latent inactive form. The resulting complex is internalized into the cancer cell to deliver the medicament within the cell.

Abstract: An implantable bioartificial pancreas device having an islet chamber containing glucose responsive and insulin-secreting islets of Langerhans or similar hormone secreting cells, one or more vascularizing chambers open to surrounding tissue, a semi-permeable membrane between the islet and vascularizing chambers that allows passage of small molecules including insulin, oxygen and glucose and does not allow passage of agents of the immune system such as white cells and antibodies, the vascularizing chambers containing a growth factor soaked fibrous or foam matrix having a porosity of about 40 to 95%, the matrix providing small capillary growth and preventing the blood from clotting in the lower chamber.